Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Subcutaneous (SC) VGA039 in Patients with Von Willebrand Disease (VWD)
Details : VGA039 is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of von Willebrand Diseases.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 11, 2025
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VGA039 is a first-in-class antibody therapy that modulates Protein S, a key co-factor involved in thrombin generation during both initiation and propagation of coagulation, it had demonstrated efficacy in numerous congenital bleeding disorders, including...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VGA039 is a first-in-class antibody therapy that modulates Protein S, a key co-factor involved in thrombin generation during both initiation and propagation of coagulation, it had demonstrated efficacy in numerous congenital bleeding disorders, including...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 06, 2023
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Details : VGA039 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of von Willebrand Diseases.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 20, 2023
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable